$GTBP Latest News - SEASONED FINANCIAL EXECUTIVE FEDERICA

New Post Public Reply Private Reply Replies (0) Message Board
jonny_red32
551
$GTBP Latest News - SEASONED FINANCIAL EXECUTIVE FEDERICA O'BRIEN JOINS GT BIOPHARMA'S BOARD OF DIRECTORS

header-logo.png

APRIL 26, 2018
LOS ANGELES, April 26, 2018 /PRNewswire/ --

GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA" , an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, today announced the addition of Federica O'Brien, CPA to GT Biopharma's board of directors effective immediately. Ms. O'Brien is expected to chair the Company's audit committee.

"We are delighted to welcome Freddi to our board of directors and look forward to the impact her invaluable experience as a CPA, biopharmaceutical chief financial officer and auditor will have on the company. Her skills will be a critical asset as we move towards a NASDAQ uplisting and other company initiatives," said Shawn M. Cross, Chairman and Chief Executive Officer of GT Biopharma.

At both private and public life science companies, Ms. O'Brien has demonstrated financial and operational leadership, and is experienced in raising capital and building infrastructures needed to support corporate growth and regulatory compliance. Further, Ms. O'Brien began her career at professional service accounting firms.

"This is a remarkable time for the development of new treatments for cancer patients with limited treatment options, and GT Biopharma has the potential to deliver long-term growth and make a significant impact delivering on these unmet medical needs," said Ms. O'Brien. "I'm delighted to work with this accomplished team."

Ms. O'Brien has held the Chief Financial Officer position at Complexa Inc., Cerecor Inc., and Cardiokine, Inc., and was Corporate Controller at Barrier Therapeutics, Inc. In addition to her position as CFO at Cervilenz, Inc., Ms. O'Brien held the position of Chief Operating Officer; she led the extension of the patent portfolio worldwide and was influential in obtaining CE marking and ISO 13485 certification for a women's healthcare device. Earlier in her career, Ms. O'Brien was CFO of Infonautics, Inc., a publicly-held technology-based company. Before specializing in life sciences and technology companies, Ms. O'Brien spent over fifteen years in professional service accounting firms, including PricewaterhouseCoopers, where she was dedicated to high growth companies in multiple industries, including the pharmaceutical industry.

Ms. O'Brien received her B.A. in Accounting from Rutgers University in 1980 and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.

About GT Biopharma, Inc.

GT Biopharma, Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms. GT's lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GT's TriKE platform will address a number of cancer types. GT's nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the effectiveness of the Company's products, the potential outcome of clinical studies, the future success of development activities, the future growth and operating and financial performance of the Company and the possibility of the Company uplisting to NASDAQ. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, obtain regulatory approval and protect its intellectual property; significant fluctuations in marketing expenses and ability to achieve or grow revenue, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products; the Company's ability to meet the applicable NASDAQ uplisting requirements, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Westwicke Partners
John Woolford
+1-(443)-213-0506
john.woolford@westwicke.com

SOURCE GT Biopharma Inc.

Released April 26, 2018

GT Biopharma Inc (GTBPD) Stock Research Links

GTBPD Board Company Profile Buy Rating Time & Sales News Filings Financials
Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment






Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Brixton Metals Delivers Promising Drill Results in Thorn Project

Updated Category News Views 167

Brixton Metals' Latest Drill Results Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) recently unveiled its second batch of drill results from the 2025 exploration season. The company operates the Thorn Project, an underexplored district known for its potential in copper-gold porphyry deposits. Highlighting Impressive Assay Results The recent drilling at the...

Continue Reading
US Labor Market Stagnation: A Closer Look at 2025 Trends

Updated Category News Views 275

November Layoffs and Hiring Trends In November, layoffs by U.S. employers reduced significantly, signaling a shift in the job market dynamics. Yet, companies are still hesitant to recruit new employees, indicating a labor market that remains restrained due to various pressures. Businesses are facing challenges such as soft demand, tariff implications, and soaring...

Continue Reading
Dollar Steady Amid Global Market Uncertainty and Yuan Weakness

Updated Category News Views 127

Asian Currency Markets React to U.S. Dollar Strength In the bustling arena of Asian currencies, the atmosphere is charged with anticipation as investors monitor the situation in China regarding potential economic stimulus measures. Meanwhile, the U.S. dollar is exhibiting remarkable strength, currently hovering near a two-and-a-half month high. This rise comes in light of...

Continue Reading
Understanding Recent Insider Trades at Omega Healthcare Invts

Updated Category News Views 75

Examining Insider Trades at Omega Healthcare Invts Recently, a notable insider trade involving Omega Healthcare Invts has drawn attention. Chief Operating Officer Daniel Booth executed a significant transaction, selling 56,725 shares as disclosed through an SEC filing. This particular sale took place on a recent date and revealed a total transaction value of $2,283,181....

Continue Reading
Exploring Future Growth in Healthcare Digital Payments Market

Updated Category News Views 150

Introduction to Digital Payments in Healthcare The transformation in the realm of healthcare is not just about treatments and services; it extends deeply into how payments are managed. The Digital Payment in Healthcare Market is evolving, with an anticipated growth in value reaching USD 61,521.8 Million by the year 2033. This incredible increase is projected to occur at a...

Continue Reading